The biotech industry is evolving rapidly with significant developments in various companies. Ocular Therapeutix announces a CEO transition, Regeneron invests $500 million in a new venture capital firm, and Marinus Pharmaceuticals faces setbacks in a Phase 3 study. Neumora Therapeutics halts a Phase 1 study due to safety concerns. Vir Biotechnology shifts focus from infectious diseases to cancer, while a hedge fund profits from Seagen’s acquisition. Colorado legislators amend a bill on rare disease drug cost caps. A biotech CEO is sentenced to seven years in prison for false claims about a rapid Covid test. EU approves Illumina’s plan to divest Grail.
Source link
Readout newsletter: Vir, Pfizer, Seagan
